Intensive cardiac management such as pharmacological intervention for ductal patency
(indomethacin and/or mefenamic acid for closure and prostaglandin E1 for maintenance) …

Management of neonates with trisomy 18 is controversial, supposedly due to the prognosis
and the lack of precise clinical information concerning efficacy of treatment. To delineate the …

Background The purpose of this study is to report short-and long-term outcomes after
congenital heart defect (CHD) interventions in patients with trisomy 13 or 18. Methods A …

Trisomy 18 (Edwards syndrome) is the second most common autosomal trisomy after
trisomy 21. Medical issues commonly include cardiac defects, such as ventricular septal …

Because of severely reduced lifespan in children with trisomies 13 and 18, surgical repair of
congenital heart lesions has rarely been offered. With data from a multicenter registry, we …

Management of neonates with trisomy 18, which is a common chromosomal abnormality, is
controversial. Withholding or withdrawal of intensive treatment (cesarean, resuscitation …

Congenital heart defects (CHD) are very common in patients with trisomy 18 (T18) and
trisomy 13 (T13). The surgical indication of CHD remains controversial since the natural …

There has been substantial controversy regarding treatment of congenital heart defects in
infants with trisomies 13 and 18. Most reports have focused on surgical outcomes versus …

The objective is to examine whether cardiac surgery should be considered for children with
trisomy 13 or 18 (T13 or 18). T13 or 18 were previously referred to as “lethal” conditions due …

Medical and surgical approaches to children with trisomy 13 and 18 are evolving, and an
increasing number of patients are being considered for simple and complex cardiac …